Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension

Massimo Volpe, Alejandro De La Sierra, Bettina Ammentorp, Petra Laeis

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP)

Original languageEnglish
Pages (from-to)561-574
Number of pages14
JournalAdvances in Therapy
Volume31
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • Cardiology
  • Hypertension
  • Olmesartan/amlodipine/hydrochlorothiazide
  • Open-label
  • Seated diastolic blood pressure
  • Seated systolic blood pressure
  • Triple combination

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension'. Together they form a unique fingerprint.

Cite this